Dustin Sjuts - Revance Therapeutics, Vice President of Strategy and Sales
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
President
Mr. Dustin Sjuts is Vice President of Strategy and Sales of the Revance Therapeutics Inc. Mr. Sjuts will head all product sales activities, championing strategies to enhance physician relations and drive new product adoption. Most recently, he held leadership positions at Nestle Skin Health, including Business Unit Head in China and Senior Director of Marketing in the U.S. In China, he was responsible for the medical aesthetics commercial organization, leading the development and execution of the medical solutions strategy. Prior to this, Mr. Sjuts was Senior Vice President of Franchise Operations for Alphaeon. Previously, he served as Director of Sales in Eye Care and as Senior Regional Manager of Aesthetics at Allergan. since 2018.
| Age | 44 |
| Tenure | 7 years |
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Dustin Sjuts Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dustin Sjuts against Revance Therapeutics, stock is an integral part of due diligence when investing in Revance Therapeutics,. Dustin Sjuts insider activity provides valuable insight into whether Revance Therapeutics, is net buyers or sellers over its current business cycle. Note, Revance Therapeutics, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revance Therapeutics,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dustin Sjuts over a year ago Acquisition by Dustin Sjuts of 264 shares of Revance subject to Rule 16b-3 | ||
Dustin Sjuts over a year ago Payment of 4712 shares by Dustin Sjuts of Revance subject to Rule 16b-3 | ||
Dustin Sjuts over a year ago Acquisition by Dustin Sjuts of 22620 shares of Revance subject to Rule 16b-3 | ||
Dustin Sjuts over a year ago Acquisition by Dustin Sjuts of 1000 shares of Revance subject to Rule 16b-3 |
Revance Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance Therapeutics,'s management efficiency ratios could be used to measure how well Revance Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Revance Therapeutics, currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance Therapeutics, has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance Therapeutics,'s use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Victoria Brown | Apellis Pharmaceuticals | 45 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Meredith Kaya | Apellis Pharmaceuticals | N/A | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Fouad MD | Blueprint Medicines Corp | 56 | |
Management Performance
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 |
Revance Therapeutics, Leadership Team
Elected by the shareholders, the Revance Therapeutics,'s board of directors comprises two types of representatives: Revance Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance Therapeutics,'s management team and ensure that shareholders' interests are well served. Revance Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |